Gaudium IVF IPO Opens Weak, Subscribed 0.87x on Day 1

Gaudium IVF and Women Health Limited's initial public offering (IPO) has demonstrated weak investor interest on its first day of subscription. The stock price band is set at ₹75-79 per share. The ₹165.00 crore IPO reached 0.87 times by 4:49:34 PM on day one. This indicates cautious investor interest in this company engaged in In Vitro Fertilisation (IVF) treatments throughout India, which has expanded into several states utilising a hub-and-spoke model, incorporated in March 2015.

Gaudium IVF IPO subscription reached weak 0.87 times on day one. It was led by Retail Investors (1.36x), Non-Institutional Investors (0.90x), and Qualified Institutional Buyers Ex-Anchor (0.00x). Total applications reached 41,017.

Invest in Indian Markets and Unlock Future Potential With 5paisa!

Open Account Now

Subscription Status of Gaudium IVF IPO:

Here are the subscription details for Gaudium IVF IPO as of Day 1 (February 20, 2026, 4:49:34 PM):

Key Highlights - Day 1:

• Overall subscription reached weak 0.87 times, showing cautious initial investor interest for this mainboard IPO
• Retail investors displaying moderate performance at 1.36 times, indicating moderate retail appetite for this IVF and women health services provider on day one
• Non-institutional investors showing weak performance at 0.90 times, indicating weak HNI interest
• Qualified institutional buyers (ex-anchor) displaying negligible performance at 0.00 times, indicating no institutional interest on day one
• Total applications reached 41,017, showing moderate investor participation for this mainboard IPO on day one
• Cumulative bid amount reached ₹100.75 crores, significantly below the net offer size of ₹115.50 crores (excluding anchor portion)
• Anchor investors fully subscribed their allocation of ₹49.50 crores on February 19, 2026

About Gaudium IVF and Women Health Limited

Incorporated in March 2015, Gaudium IVF and Women Health Limited have engaged in In Vitro Fertilisation (IVF) treatments throughout India and have expanded into several states utilising a hub-and-spoke model. The company operates over 30 locations, which include seven hubs (centres) and 28 spokes. The organisation has entered into a strategic alliance with infertility experts, known as spokes, to achieve the mutual objective of raising awareness regarding Assisted Reproductive Technology (ART) and In Vitro Fertilisation (IVF) treatments.